HARVONI (ledipasvir/sofosbuvir) Coupon & Price

HARVONI (ledipasvir/sofosbuvir) Coupon & Price
( visit store )
0 0
Comments Off
Want to say something? Add Comment 

Harvoni (ledipasvir/sofosbuvir) Coupon & Price

Harvoni is an antiviral medicine that is used to treat hepatitis C (a long-lasting chronic hepatitis C virus infection that affects the liver) in adults. One way to save money on the Harvoni retail price regardless of income and insurance status is to use Harvoni coupon. Use this ledipasvir/sofosbuvir coupon at this online pharmacy and receive up to 75% off the sale price.

Harvoni is an antiviral medicine that is used to treat hepatitis C (a long-lasting chronic hepatitis C virus infection that affects the liver) in adults.

What is Harvoni and what is it used for?

Harvoni is an antiviral medicine that is used to treat hepatitis C (a long-lasting chronic hepatitis C virus infection that affects the liver) in adults.
Harvoni contains the active substances ledipasvir and sofosbuvir.

How to use Harvoni?

Harvoni can only be obtained on a prescription basis and treatment should be initiated and supervised by a physician experienced in the management of patients with chronic hepatitis C.
Harvoni is available as tablets containing 90 mg ledipasvir and 400 mg sofosbuvir.
The recommended dose is one tablet taken once a day. There are several varieties (called genotypes) of hepatitis C virus, and Harvoni is recommended for use in patients infected with genotype 1 and genotype 4 and for some patients infected with genotype 3. Duration of treatment with Harvoni and its use alone or in combination with another drug, called ribavirin, depends on the genotype of the virus and the nature of the patient’s liver disease, for example, if they have liver cirrhosis (fibrosis) or their liver does not work properly.
For more information, see the prospectus.

How does Harvoni work?

The active substances in Harvoni, ledipasvir and sofosbuvir, block two essential proteins for the hepatitis C virus multiplication. Sofosbuvir blocks the action of an enzyme called “NS5B, RNA-dependent RNA polymerase”, while ledipasvir targets a “NS5A” protein. By blocking these proteins, Harvoni stops the hepatitis C virus multiplying and infecting new cells.
Sofosbuvir has been authorized as Sovaldi since January 2014.

What benefit has Harvoni have shown during the studies?

Harvoni was investigated in three main studies that included a total of approximately 2,000 patients infected with hepatitis C virus of genotype 1 who did not suffer from hepatic impairment. In all three studies, the main indicator of efficacy was the number of patients whose blood tests did not show signs of hepatitis C virus 12 weeks after the completion of treatment.
In these studies, patients were given Harvoni, with or without ribavirin, for 8, 12 or 24 weeks, depending on the characteristics of the patients. Approximately 94% to 99% of patients treated with Harvoni alone had a negative result in the virus screening test at 12 weeks after completion of treatment. For most patients, ribavirin was not required.

Also, the results of the studies have shown that patients with compensated liver cirrhosis (liver scarring but maintenance of liver function) were more likely to eliminate the virus when the treatment was prolonged to 24 weeks. Patients whose infection was resistant to other antiviral drugs could also benefit from 24-week treatment prolongation.
Supportive data have shown that Harvoni in combination with ribavirin may be beneficial to some patients with genotype 3, as well as for patients with genotype 1 or 4 and decompensated liver cirrhosis (liver scarring and liver failure) and / or those who have undergone a liver transplant.

What are the risks associated with Harvoni?

The most common side effects with Harvoni (which may affect more than 1 person in 10) are tiredness and headache. Harvoni should not be used with rosuvastatin, a medicine that controls cholesterol, or with St. John’s wort (a herbal preparation used to treat depression).
For the full list of side effects and restrictions associated with Harvoni, see the Package Leaflet.

Why was Harvoni approved?

The Committee for Medicinal Products for Human Use (CHMP) of the agency has decided that Harvoni’s benefits are greater than the associated risks and recommended that it be approved for use in the EU. The CHMP considered that Harvoni treatment, with or without ribavirin, has an important benefit for many patients with hepatitis C virus, including those who have had a liver transplant and / or who have compensated liver cirrhosis. Although studies in patients with decompensated liver cirrhosis are limited, these patients may benefit from prolonging treatment with Harvoni and ribavirin. As far as safety is concerned, treatment is well tolerated.

What steps are being taken to ensure safe and effective use of Harvoni?

A risk management plan has been developed for Harvoni to be used in the safest possible way. Based on this plan, safety information was included in the Summary of Product Characteristics and in the Harvon Prospectus, including the appropriate precautions to be followed by healthcare professionals and patients.
Additional information is available in the Risk Management Plan summary.

Other information about Harvoni

The European Commission granted a marketing authorization for Harvon, valid throughout the European Union on 17 November 2014.

HARVONI (ledipasvir/sofosbuvir) Coupon & Price
5 (100%) 1 vote

Comments are closed.